Cardio Diagnostics Holdings, Inc. SEC filings CDIOW

Cardio Diagnostics Holdings, Inc. has 295 filings in SEC EDGAR's recent list, going back to Jul 20, 2021. Its latest annual report, Form ARS, was filed on Jul 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (shareholder vote results). The company's fiscal year ends on December 31.

Cardio Diagnostics Holdings, Inc. SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Sep 8, 2026 —
DEFA14A Additional proxy material Aug 7, 2026 —
DEF 14A Proxy statement Aug 5, 2026 Sep 18, 2026
PRE 14A Preliminary proxy statement Jul 13, 2026 Sep 18, 2026
DEFA14A Additional proxy material Sep 4, 2025 —
DEF 14A Proxy statement Sep 4, 2025 Oct 15, 2025
PRE 14A Preliminary proxy statement Aug 13, 2025 Oct 15, 2025
DEFA14A Additional proxy material Oct 4, 2024 —
DEF 14A Proxy statement Oct 4, 2024 Nov 15, 2024
PRE 14A Preliminary proxy statement Sep 23, 2024 Nov 15, 2024
DEFA14A Additional proxy material Nov 22, 2023 —
DEF 14A Proxy statement Oct 27, 2023 Dec 4, 2023
PRE 14A Preliminary proxy statement Oct 12, 2023 Dec 15, 2023
DEF 14A Proxy statement May 3, 2023 May 2, 2023
PRE 14A Preliminary proxy statement Apr 7, 2023 Apr 7, 2023

Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as
CDIO (Nasdaq), CDIOW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Chicago, IL
SEC filer status
, Emerging growth company
SEC CIK
1870144
Former names
Mana Capital Acquisition Corp. (until Oct 26, 2022)

Other In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.